Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the use of antimüllerian hormone as a marker of ovarian reserve in infertility diagnosis and treatment, noting it reflects oocyte quantity but not health or pregnancy likelihood.

This study found that women with polycystic ovary syndrome had significantly higher serum and intrafollicular levels of anti-Müllerian hormone compared to normovulatory women, indicating a potential marker for ovarian hyperstimulation syndrome risk.

This study developed a mathematical model and online tool using serum AMH, androstenedione levels, UML, and BMI to screen for undiagnosed PCOS, particularly useful for Asian populations.

This study concluded that antimullerian hormone levels are not generally effective for distinguishing late onset congenital adrenal hyperplasia from all hyperandrogenic polycystic ovary syndrome subtypes, except one specific subtype.

This study determined that serum AMH levels are higher in women with PCOS compared to controls and may serve as a diagnostic marker for ovarian dysfunction alone or with other tools.